Currently, European guidelines for AD recommend topical (ketoconazole or ciclopirox olamine) or systemic (itraconazole or fluconazole) antifungal therapy for AD patients with HND, especially those with clear IgE sensitization to Malassezia spp. This evidence concerns the gene IGHE and Alzheimer disease.